MannKind announced a new patent issued by the USPTO covering clofazimine inhalation suspension, which is under development for the potential treatment of nontuberculous mycobacterial lung disease. The patent will expire on June 8, 2039. Pulmonary NTM infection is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life. MNKD-101 has been designated by the FDA as both an orphan drug and a qualified infectious disease product for the treatment of pulmonary NTM infections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNKD:
- MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
- MannKind initiated with Outperform on growing portfolio at Wedbush
- MannKind initiated with an Outperform at Wedbush
- MannKind Corporation Announces Participation at Upcoming Conferences
- Biotech Alert: Searches spiking for these stocks today